Altimmune Stock Is Rising Monday: What's Driving The Action?
Portfolio Pulse from Adam Eckert
Altimmune Inc (NASDAQ:ALT) shares are trading higher after the company announced positive data from its 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, showing significant weight loss and lean mass preservation. The trial results were presented at the American Diabetes Association’s 84th Scientific Sessions.
June 24, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Altimmune Inc shares rose 13.3% following the announcement of positive data from its 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, which showed significant weight loss and lean mass preservation.
The positive clinical trial results for pemvidutide, showing significant weight loss and lean mass preservation, are likely to boost investor confidence in Altimmune's product pipeline, driving the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100